Stock data
Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc. (JSPR) reported net income of -US$75.80M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$83.88M | -US$75.80M | — |
| 2024 | — | — | -US$76.24M | -US$71.27M | — |
| 2023 | — | — | -US$68.86M | -US$64.47M | — |
| 2022 | — | — | -US$51.20M | -US$37.69M | — |
| 2021 | — | — | -US$36.83M | -US$30.64M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$2.76M | — |
| 2026-03-31 | — | -US$1.17M | — |
| 2025-12-31 | — | -US$9.10M | — |
| 2025-09-30 | — | -US$18.74M | — |
| 2025-06-30 | — | -US$26.72M | — |
| 2025-03-31 | — | -US$21.24M | — |
| 2024-12-31 | — | -US$24.32M | — |
| 2024-09-30 | — | -US$18.64M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.